Ali Ajdari1, Yunhe Xie1, Christian Richter2, Maximilian Niyazi3, Dan G Duda1, Theodore S Hong1, Thomas Bortfeld1. 1. Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 2. OncoRay, National Center of Radiation Research in Oncology, Dresden, Germany. 3. Department of Radiation Oncology, Ludwig Maximilians University, Munich, Germany.
Abstract
PURPOSE: To assess the added value of serial blood biomarkers in liver metastasis stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS: Eighty-nine patients were retrospectively included. Pre- and midtreatment blood samples were analyzed for potential biomarkers of the treatment response. Three biomarker classes were studied: gene mutation status, complete blood count, and inflammatory cytokine concentration in plasma. One-year local failure (LF) and 2-year overall survival (OS) were chosen as study end points. Multivariate logistic regression was used for response prediction. Added predictive benefit was assessed by quantifying the difference between the predictive performance of a baseline model (clinicopathologic and dosimetric predictors) and that of the biomarker-enhanced model, using three metrics: (1) likelihood ratio, (2) predictive variance, and (3) area under the receiver operating characteristic curve (AUC). RESULTS: The most important predictors of LF were mutation in KRAS gene (hazard ratio [HR] = 2.92, 95% CI, [1.17 to 7.28], P = .02) and baseline and midtreatment concentration of plasma interleukin-6 (HR = 1.15 [1.04 to 1.26] and 1.06 [1.01 to 1.13], P = .01). Absolute lymphocyte count and platelet-to-lymphocyte ratio at baseline as well as neutrophil-to-lymphocyte ratio at baseline and before fraction 3 (HR = 1.33 [1.16 to 1.51] and 1.19 [1.09 to 1.30]) had the most significant association with OS (P = .0003). Addition of baseline GEN and inflammatory plasma cytokine biomarkers in predicting LF, respectively, increased AUC by 0.06 (from 0.73 to 0.79) and 0.07 (from 0.77 to 0.84). In predicting OS, inclusion of midtreatment complete blood count biomarkers increased AUC from 0.72 to 0.80, along with significant boosts in likelihood ratio and predictive variance. CONCLUSION: Inclusion of serial blood biomarkers leads to significant gain in predicting response to liver metastasis stereotactic body radiation therapy and can guide treatment personalization.
PURPOSE: To assess the added value of serial blood biomarkers in liver metastasis stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS: Eighty-nine patients were retrospectively included. Pre- and midtreatment blood samples were analyzed for potential biomarkers of the treatment response. Three biomarker classes were studied: gene mutation status, complete blood count, and inflammatory cytokine concentration in plasma. One-year local failure (LF) and 2-year overall survival (OS) were chosen as study end points. Multivariate logistic regression was used for response prediction. Added predictive benefit was assessed by quantifying the difference between the predictive performance of a baseline model (clinicopathologic and dosimetric predictors) and that of the biomarker-enhanced model, using three metrics: (1) likelihood ratio, (2) predictive variance, and (3) area under the receiver operating characteristic curve (AUC). RESULTS: The most important predictors of LF were mutation in KRAS gene (hazard ratio [HR] = 2.92, 95% CI, [1.17 to 7.28], P = .02) and baseline and midtreatment concentration of plasma interleukin-6 (HR = 1.15 [1.04 to 1.26] and 1.06 [1.01 to 1.13], P = .01). Absolute lymphocyte count and platelet-to-lymphocyte ratio at baseline as well as neutrophil-to-lymphocyte ratio at baseline and before fraction 3 (HR = 1.33 [1.16 to 1.51] and 1.19 [1.09 to 1.30]) had the most significant association with OS (P = .0003). Addition of baseline GEN and inflammatory plasma cytokine biomarkers in predicting LF, respectively, increased AUC by 0.06 (from 0.73 to 0.79) and 0.07 (from 0.77 to 0.84). In predicting OS, inclusion of midtreatment complete blood count biomarkers increased AUC from 0.72 to 0.80, along with significant boosts in likelihood ratio and predictive variance. CONCLUSION: Inclusion of serial blood biomarkers leads to significant gain in predicting response to liver metastasis stereotactic body radiation therapy and can guide treatment personalization.
Authors: Ewout W Steyerberg; Michael J Pencina; Hester F Lingsma; Michael W Kattan; Andrew J Vickers; Ben Van Calster Journal: Eur J Clin Invest Date: 2011-07-05 Impact factor: 4.686
Authors: Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano Journal: Cancer Res Date: 2013-10-04 Impact factor: 12.701
Authors: Zachary C Hartman; Graham M Poage; Petra den Hollander; Anna Tsimelzon; Jamal Hill; Nattapon Panupinthu; Yun Zhang; Abhijit Mazumdar; Susan G Hilsenbeck; Gordon B Mills; Powel H Brown Journal: Cancer Res Date: 2013-04-30 Impact factor: 12.701
Authors: Jan Budczies; Moritz von Winterfeld; Frederick Klauschen; Michael Bockmayr; Jochen K Lennerz; Carsten Denkert; Thomas Wolf; Arne Warth; Manfred Dietel; Ioannis Anagnostopoulos; Wilko Weichert; Daniel Wittschieber; Albrecht Stenzinger Journal: Oncotarget Date: 2015-01-01
Authors: P Hoegen; K S Zhang; E Tonndorf-Martini; F Weykamp; S Regnery; P Naumann; K Lang; J Ristau; S A Körber; C Dreher; C Buchele; C Rippke; C K Renkamp; K M Paul; L König; C Büsch; J Krisam; O Sedlaczek; H-P Schlemmer; M Niyazi; S Corradini; J Debus; S Klüter; J Hörner-Rieber Journal: Radiat Oncol Date: 2022-03-27 Impact factor: 3.481